Dependence on approved products
ARIKAYCE and BRINSUPRI are the main commercial assets and drive current sales.
- Scope
- Commercial revenue concentration
- Materiality
- high
INSMED Inc
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases. Its current business centers on marketed products ARIKAYCE and BRINSUPRI, while it also advances clinical and pre-clinical programs in respiratory, inflammation & immunology, and neuro/rare disease areas.
−203,9 %
79,7 %
−210,5 %
+66,7 %
3.83
3.54
| % | |
|---|---|
| Commercial respiratory products | 100% Approved products sold today, led by ARIKAYCE and BRINSUPRI. |
| Respiratory clinical-stage programs | 0% Programs such as TPIP and INS1148 aimed at pulmonary and inflammatory airway diseases. |
| Inflammation & immunology pipeline | 0% Brensocatib development work targeting hidradenitis suppurativa and related inflammatory disease. |
| Neuro & rare disease gene therapy | 0% INS1201 and INS1202 programs for DMD and ALS, respectively. |
INSMED sells primarily to healthcare providers and the specialty pharmacy / distributor channels that support...
- Specialty respiratory prescribersprimary
Pulmonologists and related specialists prescribe ARIKAYCE for refractory MAC lung disease and will be key for future respiratory launches.
- Specialty pharmacy and distributor networkprimary
Channel partners purchase, stock, and dispense product, making them central to revenue realization and patient access.
- Payers and government reimbursement programsprimary
Commercial insurers and public programs affect formulary access, rebates, and patient affordability for ARIKAYCE and BRINSUPRI.
- Clinical investigators and trial centerssecondary
Sites enrolling patients in TPIP, INS1148, INS1201, and INS1202 studies support pipeline advancement.
INSMED commercializes ARIKAYCE in the U.S., Europe, and Japan, and BRINSUPRI in the U.S...
- •U.S. is the core market for BRINSUPRI and a major ARIKAYCE market
- •Europe and Japan are established ARIKAYCE commercialization regions
- •Future expansion depends on regulatory approvals in additional countries
- •Patent protection is pursued in key markets including China and India
- •Commercialization relies on local market access and distributor execution
INSMED is focused on growing revenue from its approved products while advancing a broader pipeline in respiratory,...
01
Commercialize approved products more broadlyshort-term
ARIKAYCE and BRINSUPRI are the only current revenue engines and fund the pipeline.
02
Advance late- and mid-stage pipeline assetsmedium-term
New approvals are needed to diversify revenue and reduce dependence on current products.
03
Build long-term rare disease and gene therapy optionalitylong-term
INS1201 and INS1202 could create new therapeutic franchises if clinical data are positive.
INSMED is highly dependent on the commercial success and regulatory status of ARIKAYCE and BRINSUPRI, so any setback in...
Regulatory and clinical development failure
Pipeline value depends on successful trials and approvals for TPIP, brensocatib, and gene therapies.
- Scope
- Pipeline programs
- Materiality
- high
Customer concentration
The three largest customers represented a very large share of gross product revenue.
- Scope
- Distributor and channel relationships
- Materiality
- high
Manufacturing and supply dependence
Commercial supply relies on CMOs such as Patheon and API suppliers such as Esteve.
- Scope
- ARIKAYCE and BRINSUPRI supply chain
- Materiality
- medium
Competitive pressure
Respiratory and rare disease markets include larger pharma and biotech competitors with more resources.
- Scope
- NTM, PAH, HS, DMD, ALS
- Materiality
- medium
Gross-to-net revenue reserves
Affects reported ARIKAYCE and BRINSUPRI revenue
Contingent consideration fair value
Can drive large non-cash gains or losses in earnings
Goodwill and intangible impairment
Potential non-cash charges to operating results
Revenue timing and quarterly volatility
Makes period-to-period comparison less stable
: 28.4.2026